Digital Biomanufacturing Market Growth Fueled by Biologics & Bioprocessing 4.0
According to a new market research report, the Digital Biomanufacturing Market is projected to reach USD 76.4 billion by 2035, growing from an estimated USD 23.4 billion in 2025, at a robust CAGR of 12.6% during the forecast period from 2025 to 2035.
The
strong growth of the digital
biomanufacturing market is primarily driven by the escalating demand
for biologics, increasing capacity expansions of biopharmaceutical
manufacturing plants, and the growing focus on continuous and data-driven
bioprocessing. The rising production of monoclonal antibodies, vaccines, gene
therapies, and cellular-based biologics is pushing manufacturers to adopt
advanced digital technologies to improve efficiency, scalability, and
regulatory compliance.
Growing
Demand for Biologics Accelerates Digital Adoption
Biologics
have become a cornerstone of modern therapeutics, particularly in oncology,
immunology, rare diseases, and personalized medicine. Their complex
manufacturing requirements necessitate real-time monitoring, advanced
analytics, and process optimization—capabilities that digital biomanufacturing
platforms provide effectively. Technologies such as digital twins,
Manufacturing Execution Systems (MES), and Process Analytical Technology (PAT)
enable manufacturers to optimize production workflows, reduce variability, and
accelerate time-to-market while ensuring product quality and patient safety.
Capacity
Expansions Drive Smart Manufacturing Investments
Leading
biopharmaceutical companies are heavily investing in capacity expansion
initiatives, with a strong emphasis on digital transformation. Rather than
merely expanding physical infrastructure, companies are building intelligent,
interconnected manufacturing ecosystems that leverage predictive maintenance,
advanced analytics, and real-time quality monitoring. These digital strategies
help reduce commissioning time, enhance operational flexibility, and improve
overall equipment effectiveness (OEE), resulting in higher yields and lower
production costs.
AI,
Machine Learning, and Cloud Platforms Reshape Biomanufacturing
The
integration of artificial intelligence (AI) and machine learning (ML) is
emerging as a key trend in digital biomanufacturing. These technologies enable
predictive quality control, autonomous process optimization, and proactive
maintenance by analyzing large volumes of manufacturing data. In parallel,
cloud-based manufacturing platforms are gaining traction due to their
scalability, cost efficiency, and ability to support real-time collaboration
across global manufacturing networks.
Bioprocessing
4.0 Creates New Growth Opportunities
The
shift toward Bioprocessing 4.0, characterized by end-to-end digital
connectivity and Industrial Internet of Things (IIoT) integration, is creating
significant growth opportunities. Digital biomanufacturing solutions support
automated monitoring, reduced manual intervention, enhanced process control,
and improved compliance—making them essential for next-generation
biopharmaceutical manufacturing.
Key
Market Findings
By
Offering: The software segment is expected to account for the largest share of
the market in 2025, driven by the adoption of MES, digital twin platforms, and
advanced analytics solutions.
By
Functionality: Process optimization & analytics is projected to dominate
the market due to its ability to improve yields, reduce costs, and minimize
batch failures.
By
Bioprocess: The upstream bioprocess segment is expected to hold the largest
share, owing to the complexity and economic impact of cell culture operations.
By
Application: Monoclonal antibodies are anticipated to represent the largest
application segment in 2025, while gene-based biologics are expected to witness
the fastest growth.
By End
User: Biopharmaceutical companies are projected to dominate the market due to
increasing adoption of digital technologies to scale biologics production.
North
America Leads the Market
North
America is expected to account for the largest share of the digital
biomanufacturing market in 2025, supported by the presence of leading
biopharmaceutical companies, advanced technological infrastructure, and
favorable regulatory frameworks. However, the Asia-Pacific region is projected
to register the fastest growth, driven by expanding biopharmaceutical
manufacturing capacity and increasing government investments in biotechnology.
Key
Players
Major
companies operating in the global digital biomanufacturing market include GE
Healthcare Technologies Inc., Siemens Xcelerator, Cytiva, ABB Ltd., Sanofi
S.A., Emerson Electric Co., Honeywell International Inc., SAP SE, Schneider
Electric SE, Dassault Systèmes, Oracle Corporation, and 3M, among others.
Download sample
report here: https://www.meticulousresearch.com/download-sample-report/cp_id=5971
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment